Reviews/Polyphenols and Antioxidants/Beta-carotene raises smoker lung cancer risk
Canc · POLY-CAN-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The evidence here points one way: in a large randomized trial of male smokers, taking beta-carotene supplements was linked to more lung cancer, and this held no matter the tar or nicotine level of the cigarettes smoked [1][3]. A separate randomized follow-up in older patients found beta-carotene nearly doubled the odds of lung cancer [14], and a small tissue study offered a possible biological explanation [8]. The panel found the direction completely consistent and the smoker population an exact match in the main trial. It held back from the very top because most of the supporting papers come from that one trial, and the main trial's primary result appears only as a conference abstract. Nothing in the corpus pointed the other way.
The ATBC randomized trial in 29,133 male smokers found beta-carotene supplementation raised lung cancer incidence, with higher risk present across every category of cigarette tar and nicotine content [1][3]; the conference abstract reports this as an 18% increase [3]. An independent randomized follow-up, AREDS2, reported a lung cancer odds ratio of 1.82 (95% CI, 1.06-3.12) for those assigned beta-carotene [14]. A molecular-marker substudy of 82 ATBC lung-cancer cases offers a mechanistic correlate through aberrant cell growth [8]. The direction is unanimous across all included papers, with no contrary signal in the corpus. The contested point: The division is not over direction but over independence and reporting: three of the four included papers [1][3][8] come from the single ATBC trial, and the headline 18% figure sits only in a conference abstract [3] rather than a full primary report. The individual stratified hazard ratios shown in [1] (e.g. 1.31, 95% CI 0.91-1.89; 1.22, 95% CI 0.91-1.64) cross 1.0, so the significance rests on pooled data not shown in the corpus.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Polyphenols and Antioxidants, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Three of the four included papers ([1], [3], [8]) derive from a single trial (ATBC); the apparent evidential weight rests largely on one study plus one independent trial ([14]), limiting replication breadth within this corpus.
The primary ATBC endpoint paper is absent; the headline 18% increase appears only in a conference abstract ([3]) as background rather than as a full peer-reviewed primary report in the corpus.
Where it remains uncertain. Most of the supporting evidence derives from one trial (ATBC) [1][3][8], and that trial's primary result appears only in a conference abstract [3], while the stratified hazard ratios individually cross 1.0 [1].
Aleatory
The stratified hazard ratios in [1] carry wide confidence intervals that individually cross 1.0 (e.g. 1.31, 95% CI 0.91-1.89), reflecting sampling variability within strata.
Epistemic
Three of four included papers [1][3][8] derive from the single ATBC trial, so replication breadth within this corpus is limited to one additional independent trial [14].
Inferential
AREDS2 enrolled older AMD patients, not exclusively current smokers [14][5], so extending its OR 1.82 to the claim's smoker scope requires an inferential step.
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary ATBC evidence in the exact population (male smokers): β-carotene increases lung cancer risk, direction consistent across all strata.
“These findings support the conclusion that supplementation with β-carotene increases the risk of lung cancer in smokers regardless of the tar or nicotine content of cigarettes smoked.”
Panel auditInternal validity: high · scope of inference: Finnish male smokers aged 50-69; whether β-carotene's lung cancer effect varies by cigarette tar/nicotine contentKey limitations: subgroup HR confidence intervals cross 1.0 · male smokers only · single-country cohort
States the ATBC primary magnitude (18% incidence increase) directly in smokers.
“the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, demonstrated that β-carotene supplementation increased lung cancer incidence by 18% in smokers, and led to an 8% excess in overall mortality.”
Panel auditInternal validity: high · scope of inference: Finnish male smokers aged 50-69; β-carotene and lung cancer incidence by cigarette tar/nicotineKey limitations: conference abstract · subgroup CIs cross 1.0 · male smokers only
Mechanistic substudy corroborating the adverse lung-cancer effect observed in primary prevention trials of smokers.
“Two primary prevention trials unexpectedly showed adverse effects of supplemental beta-carotene on lung cancer incidence in cigarette smokers.”
Panel auditInternal validity: low · scope of inference: Male smokers with incident NSCLC in ATBC; molecular mechanism (aberrant cell growth) possibly underlying β-carotene harmKey limitations: mechanistic tissue markers, not incidence · very small numbers · authors call for confirmation
3 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Two independent RCTs carry the claim with unanimous direction and exact population match in ATBC, discounted modestly from the top of the band because the corpus is ATBC-concentrated and the primary endpoint report is present only as a conference abstract.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication beyond ATBC. Three of four included papers derive from one trial [1][3][8], limiting replication breadth to a single additional trial [14]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Add independent randomized trials of beta-carotene supplementation with lung cancer endpoints in smoker populations.
Open question: What is the overall, non-stratified effect size for beta-carotene on lung cancer incidence in the ATBC trial? Why it is still open: The corpus shows only stratified subgroup HRs that cross 1.0 [1] and an 18% figure from an abstract [3]; the full primary estimate is absent.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19